Massivemarkets

VIR

Vir Biotechnology, Inc. Common Stock

Nasdaq · usd

$9.25-0.33 (-3.44%)
At close · 15-minute delayed
$9.40+0.15 (+1.62%)
As of 7:30:02 PM EST on Nov 17, 2026 · After hours

Vir Biotechnology, Inc. Common Stock (VIR) trades at $9.25 (-3.44%) as of 7:30:02 PM EST on Nov 17, 2026, -9.40% over the past month. Market cap is $1.64B, with 11.9 days to cover in short interest.

Stock performance

How Vir Biotechnology, Inc. Common Stock (VIR) stock has performed from one day to one year, with its 52-week range.

-3.59%
-$0.35 over 1D
$9.09$9.34$9.58$9.834:00 AM10:30 AM12:30 PM2:35 PM8:00 PM$9.40
1D
-3.44%
1W
-29.66%
1M
-9.40%
YTD
+53.40%
1Y
+68.18%
52-wk range
$5.32 – $14.38

Key statistics

Today's trading snapshot for VIR: day range, open, previous close, volume and market cap.

Day range
$9.03 – $9.75
Open
$9.58
Prev close
$9.58
Volume
3.48M
Market cap
$1.64B
Shares out
171.27M

Valuation and profitability ratios: P/E, P/S, ROE

Valuation and profitability ratios for Vir Biotechnology, Inc. Common Stock: P/E, P/S, P/B, ROE and more.

P/E
—
P/S
5.63
P/B
1.90
P/FCF
—
ROE
-20.6%
ROA
-16.6%
Debt/Equity
0.00
Div yield
0.00%

As of Nov 13, 2026

8-K filings

Material corporate events Vir Biotechnology, Inc. Common Stock has disclosed to the SEC on Form 8-K.

  • Additional Week 96 data from the Phase 2 SOLSTICE trial show that treatment with elebsiran and tobevibart drove rapid HDV RNA suppression, with 100% (28/28) of patients who completed Week 96 of combination therapy reaching undetectable viremia. Among patients with paired liver stiffness measurements, 89% (24/27) had improved or stable liver stiffness at Week 96.

  • On November 4, 2026, Vir Biotechnology, Inc. (the Company) issued a press release announcing its financial results for the quarter ended September 30, 2026.

  • Director appointmentOct 28, 2026

    On October 26, 2026, the Board of Directors (the Board) of Vir Biotechnology, Inc. (the Company) ... approved an increase in the size of the Board from eight to nine members and the appointment of Suzanne Topalian, M.D., to fill the newly created vacancy and serve on the Board as a Class III director until the Company's 2028 annual meeting of stockholders ... effective as of October 27, 2026.

  • Partnership or collaborationOct 14, 2026

    On October 9, 2026, Vir Biotechnology, Inc. (Vir Bio) and Gilead Sciences, Inc. (Gilead) entered into a Collaboration and License Agreement (the Agreement), pursuant to which Vir Bio and Gilead will enter into a global strategic collaboration to discover and engineer three novel PRO-XTEN® dual-masked T-cell engager (TCE) development candidates targeting selected solid tumor-associated antigens.

  • Partnership or collaborationOct 8, 2026

    VIR-5500 is being co-developed by Astellas Pharma Inc. and the Company through a global strategic collaboration.

VIR short interest

How heavily VIR is shorted: shares short, days to cover and average daily volume.

Days to cover
11.9
Short interest
16.87M
Avg volume
1.42M

As of · reported to FINRA twice monthly.

VIR news

The latest news and headlines about Vir Biotechnology, Inc. Common Stock (VIR).

Frequently asked questions

What is the Vir Biotechnology, Inc. Common Stock (VIR) stock price today?

Vir Biotechnology, Inc. Common Stock (VIR) is trading at $9.25 (-3.44% on the day) as of 7:30:02 PM EST on Nov 17, 2026. Prices are delayed at least 15 minutes; real-time quotes are available from the Massive API.

What is Vir Biotechnology, Inc. Common Stock?

Vir Biotechnology Inc is a clinical-stage biopharmaceutical company focused on powering the immune system by discovering and developing medicines for serious infectious diseases and cancer.

What is the short interest in VIR?

As of Oct 30, 2026, VIR has 16.87M shares short and 11.9 days to cover.

What exchange is VIR listed on?

Vir Biotechnology, Inc. Common Stock (VIR) trades on Nasdaq in USD, in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry.

Build with AI

Build an analysis of VIR with your agent

Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.

Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a VIR analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.

Live market data from the Massive API and MCP.Get a free API key

Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.